BB-201, a potent first-in-class anti-Her2/anti-Trop2 bispecific ADC candidate

Nov. 19, 2024

Researchers from Bright Biologics LLC presented the discovery and preclinical characterization of a novel bispecific anti-Her2/anti-Trop2 antibody-drug conjugate (ADC), BB-201.

BioWorld Science Conferences Society for Immunotherapy of Cancer Cancer Antibody-drug conjugate

Today's news in brief

BioWorld

BioWorld briefs for April 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 24, 2025.

Regulatory actions for April 24, 2025

BioWorld

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cel-Sci, Novavax,...

Go ask Alis? New fund aims to rescue biopharma’s trapped cash

BioWorld

“They are not zombies, they are fallen angels.” That is view of Nick Johnston, a U.K-based banker who has come up with a new plan to rescue listed companies whose...

Dan Chen, founder and CEO, Synthetic Design Lab

Synthetic Design emerges with $20M and next-gen ADC platform

BioWorld

Synthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC)...